Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The process of integrating the reverse-transcribed HIV-1 DNA into the host chromosomal DNA is catalyzed by the virally encoded enzyme integrase (IN). Integration requires two metal-dependent reactions, 3′ end processing and strand transfer. Compounds that contain a diketo acid moiety have been shown to selectively inhibit the strand transfer reaction of IN in vitro and in infected cells and are effective as inhibitors of HIV-1 replication. To characterize the molecular basis of inhibition, we used functional assays and binding assays to evaluate a series of structurally related analogs. These studies focused on investigating the role of the conserved carboxylate and metal binding. We demonstrate that an acidic moiety such as a carboxylate or isosteric heterocycle is not required for binding to the enzyme complex but is essential for inhibition and confers distinct metal-dependent properties on the inhibitor. Binding requires divalent metal and resistance is metal dependent with active site mutants displaying resistance only when the enzymes are evaluated in the context of Mg 2+ . The mechanism of action of these inhibitors is therefore likely a consequence of the interaction between the acid moiety and metal ion(s) in the IN active site, resulting in a functional sequestration of the critical metal cofactor(s). These studies thus have implications for modeling active site inhibitors of IN, designing and evaluating analogs with improved efficacy, and identifying inhibitors of other metal-dependent phosphotransferases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The INSTI pharmacophore consists of a metal chelating core - generally a co-planar triad of oxygen atoms - and a halobenzyl side chain (Fig. 5A, shown in red and blue, respectively)156.”
From Structure and function of retroviral integrase (2022) · cites this paper as [156]
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131
Self-citationDNA Polymerases: Structural Diversity and Common Mechanisms
Steitz, T. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17395 · Cited by 848
Dyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R., & Davies, D. R. (1994) · Science · doi:10.1126/science.7801124 · Cited by 810
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
Davies, J. F., Hostomska, Z., Hostomsky, Z., Jordan, S. R., & Matthews, D. A. (1991) · Science · doi:10.1126/science.1707186 · Cited by 570
Goldgur, Y., Craigie, R., Cohen, G. H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo, T., Murai, H., & Davies, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13040 · Cited by 496
Three-Dimensional Structure of the Tn 5 Synaptic Complex Transposition Intermediate
Davies, D. R., Goryshin, I. Y., Reznikoff, W. S., & Rayment, I. (2000) · Science · doi:10.1126/science.289.5476.77 · Cited by 427
Bushman, F. D., & Craigie, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1339 · Cited by 410
Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium
Goldgur, Y., Dyda, F., Hickman, A. B., Jenkins, T. M., Craigie, R., & Davies, D. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9150 · Cited by 380
Sherman, P. A., & Fyfe, J. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5119 · Cited by 334
Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317
Self-citation
Research works printed but not linked: 1
- P O Brown Retroviruses, eds J M Coffin, S H Hughes, H E Varmus (Cold Spring Harbor Lab. Press, Plainview, NY), pp. 161–203 (1997).
Cited by
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database
Shafer, R. W., Stevenson, D., & Chan, B. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.348 · Cited by 907
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
“Therefore, all InSTIs are comprised of two essential components: a metal-binding pharmacophore, which sequestors the active site magnesiums, and a hydrophobic group, which interacts with the viral DNA as well as the enzyme in the complex (Grobler et al. 2002).”
BackgroundSelf-citationHuman immunodeficiency virus reverse transcriptase and protease sequence database
Rhee, S.-Y. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg100 · Cited by 817
“A new class of compounds that inhibit HIV-1 integrase have been shown to be active in vitro and in a SHIV rhesus macaque model of infection (9,10).”
BackgroundIntegrase inhibitors to treat HIV/Aids
Pommier, Y., Johnson, A. A., & Marchand, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1660 · Cited by 688
Retroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
Summa, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M., Fiore, F., Gardelli, C., Gonzalez Paz, O., Hazuda, D. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800245z · Cited by 633
Self-citationThe structural biology of HIV-1: mechanistic and therapeutic insights
Engelman, A., & Cherepanov, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2747 · Cited by 424
“INSTIs harbour two common moieties: co-planar heteroatoms (typically three oxygen atoms) that chelate the active-site metal ion”
BackgroundHazuda, D. J., Anthony, N. J., Gomez, R. P., Jolly, S. M., Wai, J. S., Zhuang, L., Fisher, T. E., Embrey, M., Guare, J. P., Egbertson, M. S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402357101 · Cited by 333
Self-citationNovel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics
Sato, M., Motomura, T., Aramaki, H., Matsuda, T., Yamashita, M., Ito, Y., Kawakami, H., Matsuzaki, Y., Watanabe, W., Yamataka, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0600139 · Cited by 328
Twenty years of therapy for HIV-1 infection
Pomerantz, R. J., & Horn, D. L. (2003) · Nature Medicine · doi:10.1038/nm0703-867 · Cited by 284
“One promising area of interest is to target the virally encoded enzyme integrase, which catalyzes the insertion of reverse-transcribed HIV-1 DNA into the host chromosomal DN”
BackgroundZhuang, L., Wai, J. S., Embrey, M. W., Fisher, T. E., Egbertson, M. S., Payne, L. S., Guare, Vacca, J. P., Hazuda, D. J., Felock, P. J., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm025553u · Cited by 270
Self-citationHare, S., Smith, S. J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., & Cherepanov, P. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073189 · Cited by 264
“The common INSTI pharmacophore comprises a triad of coplanar heteroatoms (oxygen or nitrogen), positioned to chelate a pair of divalent metal ions (Grobler et al., 2002), and a halogenated phenyl ring that invades a pocket natively occupied by the 3 -terminal base of viral DNA (Hare et al., 2010a).”
BackgroundReguera, J., Weber, F., & Cusack, S. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001101 · Cited by 255
“Most of these compounds implicitly target the two metal binding site of the endonuclease, which is also the target for many HIV integrase inhibitors [38] including the currently approved raltegravir [39,40].”
BackgroundQuashie, P. K., Mesplède, T., Han, Y.-S., Oliveira, M., Singhroy, D. N., Fujiwara, T., Underwood, M. R., & Wainberg, M. A. (2012) · Journal of Virology · doi:10.1128/jvi.06591-11 · Cited by 237
“Even though 3= processing may be a suitable therapeutic target, the integrase inhibitors developed so far are integrase strand transfer inhibitors (INSTIs) that preferentially inhibit strand transfer while only modestly affecting 3= processing (18, 24, 26).”
BackgroundNew Approaches toward Anti-HIV Chemotherapy
De Clercq, E. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040158k · Cited by 235
Integrase and integration: biochemical activities of HIV-1 integrase
Delelis, O., Carayon, K., Saïb, A., Deprez, E., & Mouscadet, J.-F. (2008) · Retrovirology · doi:10.1186/1742-4690-5-114 · Cited by 233
“The difference between cofactors has pharmacological implications, as the apparent efficacy of various IN inhibitors differs between tests using Mg2+ or Mn2+ as a cofactor [70-72], and the effects of mutations conferring drug resistance are often detectable only in tests using Mg2+ as the cofactor [73].”
BackgroundStructure-based modeling of the functional HIV-1 intasome and its inhibition
Krishnan, L., Li, X., Naraharisetty, H. L., Hare, S., Cherepanov, P., & Engelman, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002346107 · Cited by 191
“The underlying features of the drugs, coplanar oxygen atoms and aromatic rings that tend to be halogenated (12, 13, 42), had suggested that coordination of critical divalent metal ions via pharmacophore oxygens underscores the mechanism of inhibition (38), and our results indeed highlight these interactions between RA…”
BackgroundRational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist
Li, X., Li, X., Liu, F., Li, S., & Shi, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00683 · Cited by 168
Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy
McColl, D. J., & Chen, X. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.11.004 · Cited by 173
HIV-1 reverse transcriptase and antiviral drug resistance. Part 1
Das, K., & Arnold, E. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.03.012 · Cited by 168
“Recently approved integrase inhibitors (raltegravir and elvitegravir) bind the active site of HIV-1 integrase in a pre-integration complex [5,6] and block the viral DNA integration into host cell chromosomes.”
Kowalinski, E., Zubieta, C., Wolkerstorfer, A., Szolar, O. H. J., Ruigrok, R. W. H., & Cusack, S. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002831 · Cited by 169
“It is interesting to note, however, that the HIV integrase inhibitor Raltegravir, now in clinical use, is also a diketobutanoic acid derivative and targets a two cation containing active site with some similarities to the influenza endonuclease [35–37].”
BackgroundDe Clercq, E. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.241 · Cited by 163
Bessong, P. O., Obi, C. L., Andréola, M.-L., Rojas, L. B., Pouységu, L., Igumbor, E., Meyer, J. J. M., Quideau, S., & Litvak, S. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.01.056 · Cited by 161
Pharmacophore-Based Design of HIV-1 Integrase Strand-Transfer Inhibitors
Barreca, M. L., Ferro, S., Rao, A., De Luca, L., Zappalà, M., Monforte, A.-M., Debyser, Z., Witvrouw, M., & Chimirri, A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050549e · Cited by 158
Shaw-Reid, C. A., Munshi, V., Graham, P., Wolfe, A., Witmer, M., Danzeisen, R., Olsen, D. B., Carroll, S. S., Embrey, M., Wai, J. S., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200621200 · Cited by 156
Self-citationLataillade, M., Chiarella, J., & Kozal, M. J. (2007) · Antiviral Therapy · doi:10.1177/135965350701200411 · Cited by 151
“HIV-1 retroviral integration can be described as a multistep process: (1) assembly of a stable complex between IN and specific viral DNA sequences at the end of the HIV-1 long terminal repeats, (2) 3′ processing, (3) preintegration complex translocation, (4) strand transfer, and (5) DNA gap repair and ligation [2,4].”
BackgroundBillamboz, M., Bailly, F., Lion, C., Touati, N., Vezin, H., Calmels, C., Andréola, M.-L., Christ, F., Debyser, Z., & Cotelle, P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1014692 · Cited by 138
Himmel, D. M., Maegley, K. A., Pauly, T. A., Bauman, J. D., Das, K., Dharia, C., Clark, A. D., Ryan, K., Hickey, M. J., Love, R. A., et al. (2009) · Structure · doi:10.1016/j.str.2009.09.016 · Cited by 140
“The authors postulated that this RNHI has a metal ion-dependent inhibition mechanism that is similar to that of related HIV integrase inhibitors[11].”
BackgroundResultMarinello, J., Marchand, C., Mott, B. T., Bain, A., Thomas, C. J., & Pommier, Y. (2008) · Biochemistry · doi:10.1021/bi800791q · Cited by 137
“The specificity for the ST step indicates that the drugs can selectively recognize a specific configuration of the IN-DNA complex and that they probably bind at the interface of the IN-viral DNA processed complex by forming a quaternary complex with the catalytic metal in the enzyme active site together with the 3′-pr…”
BackgroundEmerging Drug Targets for Antiretroviral Therapy
Reeves, J. D., & Piefer, A. J. (2005) · Drugs · doi:10.2165/00003495-200565130-00002 · Cited by 155
Marchand, C., Johnson, A. A., Karki, R. G., Pais, G. C. G., Zhang, X., Cowansage, K., Patel, T. A., Nicklaus, M. C., Burke, T. R., & Pommier, Y. G. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.600 · Cited by 143
“…proposed to bind a divalent metal ion in the catalytic site of the enzyme (Grobler et al., 2002; Pais et al., 2002) in a metal-dependent manner (Grobler et al., 2002), we studied the potency of DKAs for the in vitro inhibition of wild-type integrase in the presence of Mn2 versus Mg2 and…”
BackgroundInfluentialA historical sketch of the discovery and development of HIV-1 integrase inhibitors
Savarino, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.12.1507 · Cited by 141
“Researchers calculated that the crystallographic structure of the HIV-1 integrase in complex with 5-CITEP was consistent with models wherein the keto-enol group is important for establishing interactions with the two metal ions likely to be coordinated by the acidic catalytic residues [66].”
MethodDesign and Synthesis of Novel Indole β-Diketo Acid Derivatives as HIV-1 Integrase Inhibitors
Sechi, M., Derudas, M., Dallocchio, R. N., Dessì, A., Bacchi, A., Sannia, L., Carta, F., Palomba, M., Ragab, O., Chan, C., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049944f · Cited by 127
Rhee, S., Liu, T. F., Kiuchi, M., Zioni, R., Gifford, R. J., Holmes, S., & Shafer, R. W. (2008) · Retrovirology · doi:10.1186/1742-4690-5-74 · Cited by 137
“The clinically active INIs are competitive inhibitors of target DNA and indeed there is much overlap between the sites associated with target DNA binding and INI binding [28,40].”
BackgroundStructure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
Tramontano, E., Esposito, F., Badas, R., Santo, R. D., Costi, R., & Colla, P. L. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2004.11.002 · Cited by 121
Billamboz, M., Bailly, F., Barreca, M. L., De Luca, L., Mouscadet, J.-F., Calmels, C., Andréola, M.-L., Witvrouw, M., Christ, F., Debyser, Z., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8007085 · Cited by 117
Structural insights into the retroviral DNA integration apparatus
Cherepanov, P., Maertens, G. N., & Hare, S. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2010.12.005 · Cited by 118
Johns, B. A., Weatherhead, J. G., Allen, S. H., Thompson, J. B., Garvey, E. P., Foster, S. A., Jeffrey, J., & Miller, W. H. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.01.090 · Cited by 114
Antivirals Targeting Influenza A Virus
Das, K. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300455c · Cited by 123
Structural biology of retroviral DNA integration
Li, X., Krishnan, L., Cherepanov, P., & Engelman, A. (2011) · Virology · doi:10.1016/j.virol.2010.12.008 · Cited by 112
“Pipeline INSTIs were shown to bind IN–vDNA complexes with significantly higher affinity than free HIV-1 IN protein (Espeseth et al., 2000; Grobler et al., 2002), indicating that a vDNA-dependent IN conformational change (s) was critical for high affinity binding or the drugs interacted directly…”
BackgroundIntegrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
Smith, S. J., Zhao, X. Z., Passos, D. O., Lyumkis, D., Burke, T. R., & Hughes, S. H. (2021) · Viruses · doi:10.3390/v13020205 · Cited by 132
Sato, M., Kawakami, H., Motomura, T., Aramaki, H., Matsuda, T., Yamashita, M., Ito, Y., Matsuzaki, Y., Yamataka, K., Ikeda, S., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900460z · Cited by 109
Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication
Maeda, K., Das, D., Kobayakawa, T., Tamamura, H., & Takeuchi, H. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190712204603 · Cited by 126
Summa, V., Petrocchi, A., Matassa, V. G., Gardelli, C., Muraglia, E., Rowley, M., Paz, O. G., Laufer, R., Monteagudo, E. S., & Pace, P. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060854f · Cited by 104
Cole, A. L., Hossain, S., Cole, A. M., & Phanstiel, O. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.045 · Cited by 100
Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
Fenwick, C., Amad, M., Bailey, M. D., Bethell, R., Bös, M., Bonneau, P., Cordingley, M., Coulombe, R., Duan, J., Edwards, P., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02719-13 · Cited by 99
Resistance to Integrase Inhibitors
Métifiot, M., Marchand, C., Maddali, K., & Pommier, Y. (2010) · Viruses · doi:10.3390/v2071347 · Cited by 99
“As for DKA, RAL’s inhibition mechanism is specific for the ST step of integration and proposed to involve chelation of one or two metals within the IN active site after processing of the bound viral DNA ends [45,46].”
BackgroundRetroviral Integrase Proteins and HIV-1 DNA Integration
Krishnan, L., & Engelman, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.397760 · Cited by 97
“moieties engage bound-metal ion at the IN active site (67), results subsequently verified through co-crystallization of INSTIs with the PFV CDC (18,68,69).”
BackgroundHIV-chemotherapy and -prophylaxis: new drugs, leads and approaches
Clercq, E. D. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.02.015 · Cited by 113
Kawasuji, T., Johns, B. A., Yoshida, H., Weatherhead, J. G., Akiyama, T., Taishi, T., Taoda, Y., Mikamiyama-Iwata, M., Murai, H., Kiyama, R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301550c · Cited by 100
Retroviral Integrase Structure and DNA Recombination Mechanism
Engelman, A., & Cherepanov, P. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0024-2014 · Cited by 94
“The initial compounds in this drug class, which contained a common diketo acid moiety (199), chelated divalent metal ions in the active site and competed with target DNA for binding to the intasome in vitro (200, 201).”
BackgroundSechi, M., Bacchi, A., Carcelli, M., Compari, C., Duce, E., Fisicaro, E., Rogolino, D., Gates, P. J., Derudas, M., Al‐Mawsawi, L. Q., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060193m · Cited by 97
Rosemond, M. J. C., John‐Williams, L. S., Yamaguchi, T., Fujishita, T., & Walsh, J. S. A. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2003.12.001 · Cited by 94
Bar-Magen, T., Sloan, R. D., Donahue, D. A., Kuhl, B. D., Zabeida, A., Xu, H., Oliveira, M., Hazuda, D. J., & Wainberg, M. A. (2010) · Journal of Virology · doi:10.1128/jvi.01164-10 · Cited by 91
“INSTIs have been shown to chelate these critical cations in the enzyme active site and have high affinity for integrase only in the cDNA-bound state (15).”
BackgroundSelf-citationSanto, R. D., Costi, R., Roux, A., Artico, M., Lavecchia, A., Marinelli, L., Novellino, E., Palmisano, L., Andreotti, M., Amici, R., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0511583 · Cited by 94
HIV-1 ribonuclease H: structure, catalytic mechanism and inhibitors
Beilhartz, G. L., & Götte, M. (2010) · Viruses · doi:10.3390/v2040900 · Cited by 88
“Diketo acids also form a group of compounds initially developed against the structurally similar HIV-1 integrase (IN) [92,93].”
BackgroundHIV-1 IN Inhibitors: 2010 Update and Perspectives
Marchand, C., Maddali, K., Metifiot, M., & Pommier, Y. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630910 · Cited by 88
Kawasuji, T., Fuji, M., Yoshinaga, T., Sato, A., Fujiwara, T., & Kiyama, R. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.08.043 · Cited by 90
Koch, U., Attenni, B., Malancona, S., Colarusso, S., Conte, I., Filippo, M. D., Harper, S., Pacini, B., Giomini, C., Thomas, S., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051064t · Cited by 87
Savarino, A. (2007) · Retrovirology · doi:10.1186/1742-4690-4-21 · Cited by 91
“the metal thought to act as a cofactor in vivo) [18].”
BackgroundMultifaceted HIV integrase functionalities and therapeutic strategies for their inhibition
Engelman, A. N. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006901 · Cited by 78
“The conserved INSTI heteroatoms engage the divalent metal ions that are bound by the DDE active-site residues (35, 92).”
BackgroundDihydroxypyrimidine-4-carboxamides as Novel Potent and Selective HIV Integrase Inhibitors
Pace, P., Francesco, M. E. D., Gardelli, C., Harper, S., Muraglia, E., Nizi, E., Orvieto, F., Petrocchi, A., Poma, M., Rowley, M., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070027u · Cited by 80
Self-citationEmerging Pharmacology: Inhibitors of Human Immunodeficiency Virus Integration
Hazuda, D. J., Iwamoto, M., & Wenning, L. A. (2008) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145553 · Cited by 78
“Thus, sequestration of the active site metals by the pharmacophore is critical for inhibition, whereas the affinity of integrase strand transfer inhibitors appears to be determined largely (although not exclusively) by the pendant substituents (29).”
BackgroundMethodSelf-citationDidierjean, J., Isel, C., Querré, F., Mouscadet, J.-F., Aubertin, A.-M., Valnot, J.-Y., Piettre, S. R., & Marquet, R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.4884-4894.2005 · Cited by 75
“At first sight, one could expect strongly decreased inhibition with MnCl2, as the oxygen atoms and hence 3,7-dihydroxytropolones have much weaker affinity for Mn2 than for Mg2 .”
BackgroundInfluentialJohnson, A. A., Santos, W. L., Pais, G. C. G., Marchand, C., Amin, R., Burke, T. R., Verdine, G. L., & Pommier, Y. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511348200 · Cited by 86
Garvey, E. P., Johns, B. A., Gartland, M. J., Foster, S. A., Miller, W. H., Ferris, R. G., Hazen, R. J., Underwood, M., Boros, E. E., Thompson, J. B., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01218-07 · Cited by 76
“Although no crystallographic system exists to directly study the interactions between the two-metal inhibitors and integrase, there is a reasonable understanding of both the chemical pharmacophore (2, 11, 23) and the biochemical mechanism of inhibition (13, 24).”
BackgroundXue, W., Jin, X., Ning, L., Wang, M., Liu, H., & Yao, X. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300541c · Cited by 74
Le Grice, S. F. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.389056 · Cited by 73
“Originally developed as metal-dependent inhibitors of HIV-1 integrase (80, 81), compounds containing a diketo acidmoiety aremoderately effective RNaseH inhibitors, among which RDS 1643 inhibited RNase H activity and prevented HIV replication in cell culture with an EC50 of 14 M (82).”
BackgroundResistance to HIV-1 integrase inhibitors: A structural perspective
Mouscadet, J. F., Delelis, O., Marcelin, A., & Tchertanov, L. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.05.001 · Cited by 84
“Mg2+ plays an important role in the catalysis mediated by integrase, and this has led to the incorporation of Mg-chelating functions into the rational design of INSTIs (Grobler et al., 2002).”
BackgroundHIV Integrase Inhibitors with Nucleobase Scaffolds: Discovery of a Highly Potent Anti-HIV Agent
Nair, V., Chi, G., Ptak, R. G., & Neamati, N. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0508890 · Cited by 73
HIV integrase inhibitors as therapeutic agents in AIDS
Nair, V., & Chi, G. (2007) · Reviews in Medical Virology · doi:10.1002/rmv.539 · Cited by 72
Raltegravir: an integrase inhibitor for HIV-1
Evering, T. H., & Markowitz, M. H. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.413 · Cited by 69
Das, K., Martinez, S. E., Bandwar, R. P., & Arnold, E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku487 · Cited by 68
Gardelli, C., Nizi, E., Muraglia, E., Crescenzi, B., Ferrara, M., Orvieto, F., Pace, P., Pescatore, G., Poma, M., Ferreira, M. D. R. R., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0704705 · Cited by 67
Self-citationDesign and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors
Sechi, M., Rizzi, G., Bacchi, A., Carcelli, M., Rogolino, D., Pala, N., Sanchez, T. W., Taheri, L., Dayam, R., & Neamati, N. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.088 · Cited by 66
HIV integrase as a target for antiretroviral therapy
Hazuda, D. J. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283567309 · Cited by 63
Self-citationAllosteric Inhibitor Development Targeting HIV‐1 Integrase
Al‐Mawsawi, L. Q., & Neamati, N. (2011) · ChemMedChem · doi:10.1002/cmdc.201000443 · Cited by 61
Barreca, M. L., Iraci, N., Luca, L. D., & Chimirri, A. (2009) · ChemMedChem · doi:10.1002/cmdc.200900166 · Cited by 70
Kawasuji, T., Johns, B. A., Yoshida, H., Taishi, T., Taoda, Y., Murai, H., Kiyama, R., Fuji, M., Yoshinaga, T., Seki, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3010459 · Cited by 61
Azido-Containing aryl β-Diketo acid HIV-1 integrase inhibitors
Zhang, X., Pais, G. C. G., Svarovskaia, E. S., Marchand, C., Johnson, A. A., Karki, R. G., Nicklaus, M. C., Pathak, V. K., Pommier, Y. G., & Burke, T. R. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00059-3 · Cited by 60
The development of novel HIV integrase inhibitors and the problem of drug resistance
Wainberg, M. A., Mésplède, T., & Quashie, P. K. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.08.007 · Cited by 71
Williams, P. D., Staas, D. D., Venkatraman, S., Loughran, H. M., Ruzek, R. D., Booth, T. M., Lyle, T. A., Wai, J. S. M., Vacca, J. P., Feuston, B. P., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.135 · Cited by 59
Self-citationDesign of Novel Bioisosteres of β-Diketo Acid Inhibitors of HIV-1 Integrase
Sechi, M., Sannia, L., Carta, F., Palomba, M., Dallocchio, R. N., Dessì, A., Derudas, M., Zawahir, Z., & Neamati, N. (2005) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020501600105 · Cited by 63
“Chelation of metal co-factors have been implicated for diketo acids-based inhibitors (Grobler et al., 2002; Pais et al., 2002; Long et al., 2004; Marchand et al., 2003; Maurin et al., 2003) and proposed for some other related classes of inhibitors (Neamati et al., 1998, 2001, 2002; Zhao et., 1997,…”
BackgroundResistance to HIV integrase inhibitors
Mésplède, T., Quashie, P. K., & Wainberg, M. A. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328356db89 · Cited by 63
Singh, A. K., & Das, K. (2022) · Viruses · doi:10.3390/v14051027 · Cited by 58
Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design
Karki, R. G., Tang, Y., Burke, T. R., & Nicklaus, M. C. (2004) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-005-0365-5 · Cited by 64
Семенова, Е. А., Johnson, A. A., Marchand, C., Davis, D. A., Yarchoan, R., & Pommier, Y. G. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020321 · Cited by 59
“…on July 6, 2017 m olpharm .aspetjournals.org D ow nloaded from The ST inhibitors 5-chloroindolyltetrazolylpropenone and L-731,988 have been proposed to chelate the divalent metal cations (Mg2 or Mn2 ) in the enzyme active site (Grobler et al., 2002; Marchand et al., 2003; Pommier et al., 2005).”
BackgroundInfluentialDesign and Optimization of Tricyclic Phtalimide Analogues as Novel Inhibitors of HIV-1 Integrase
Verschueren, W. G., Dierynck, I., Amssoms, K., Hu, L., Boonants, P. M. J. G., Pille, G. M. E., Daeyaert, F. F. D., Hertogs, K., Surleraux, D. L. N. G., & Wigerinck, P. B. T. P. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049559q · Cited by 58
Deanda, F., Hightower, K. E., Nolte, R. T., Hattori, K., Yoshinaga, T., Kawasuji, T., & Underwood, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077448 · Cited by 64
“Consistent with previous reports [31,32] is that the 3 IN inhibitors share common pharmacophoric features essential for binding to the active site.”
1 The Discovery of Raltegravir, an Integrase Inhibitor for the Treatment of HIV Infection
Rowley, M. (2008) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(07)00001-x · Cited by 58
Bar-Magen, T., Donahue, D. A., McDonough, E. I., Kuhl, B. D., Faltenbacher, V. H., Xu, H., Michaud, V., Sloan, R. D., & Wainberg, M. A. (2010) · AIDS · doi:10.1097/qad.0b013e32833cf265 · Cited by 60
“2174 AIDS 2010, Vol 24 No 14 MgCl2, and 50 mg/ml BSA [6,39] and the plate was incubated at 378C for 1 h. Covalently linked target DNA was detected through use of an anti-FITC antibody conjugated to alkaline phosphatase (Roche) and a chemiluminescence substrate (CSPD Sapphire II, Applied Biosystems).”
MethodQuinoline-based HIV Integrase Inhibitors
Musioł, R. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319100008 · Cited by 61
Dayam, R., & Neamati, N. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.09.035 · Cited by 61
The Hunt for HIV-1 Integrase Inhibitors
Lataillade, M., & Kozal, M. J. (2006) · AIDS Patient Care and STDs · doi:10.1089/apc.2006.20.489 · Cited by 68
“30,35”
Bacchi, A., Biemmi, M., Carcelli, M., Carta, F., Compari, C., Fisicaro, E., Rogolino, D., Sechi, M., Sippel, M., Sotriffer, C., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800893q · Cited by 57
Tomei, L., Altamura, S., Paonessa, G., Francesco, R. D., & Migliaccio, G. (2005) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020501600403 · Cited by 64
“…transfer of a phosphoryl group via the so-called two-metal-ion mechanism, including the HIV and HBV polymerases, the influenza virus endonuclease, the HIV integrase and HIV RNase H (Grobler et al., 2002; Altamura et al., 2000; Hazuda et al., 2000; Shaw-Reid et al., 2003; Tomassini et al., 1994).”
BackgroundThe next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets
Turpin, J. A. (2003) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.1.1.97 · Cited by 62
Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity
Ilina, T., LaBarge, K., Sarafianos, S. G., Ishima, R., & Parniak, M. A. (2012) · Biology · doi:10.3390/biology1030521 · Cited by 54
“The diketo acid (DKA) pharmacophore (Table 1, structure 1) arose from the Merck integrase (IN) inhibitor development program [20,21].”
BackgroundAdvances in two-metal chelation inhibitors of HIV integrase
Johns, B. A., & Svolto, A. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.11.1225 · Cited by 54
“This consists of a planar heteroatom two-metal chelation region that binds to a pair of divalent magnesium metal centers held in place by a triad of amino acid carboxylate residues (D116/D64/E152), a flexible linker, and a hydrophobic aromatic substituent [11,12] .”
Background
Metadata
- Authors
- Grobler, J. A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., Wai, J. S., Young, S., Vacca, J., & Hazuda, D. J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Tufts University (US)
- Corresponding author
- Hazuda, Daria J.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-05-07
- Volume
- 99
- Issue
- 10
- Pages
- 6661-6666
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC124459
- OpenAlex
- W2117959947
- Cited by
- 399
- References
- 32
- Citations by year
- 2026: 3 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 4 · 2018: 13 · 2017: 8 · 2016: 12 · 2015: 18 · 2014: 17 · 2013: 18 · 2012: 26
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- HIV-1 integrase, strand transfer inhibition, metal-dependent enzyme activity, magnesium cofactor, carboxylate binding, reverse transcription, inhibitor mechanism of action
- MeSH terms
- Binding, Competitive, Humans, Ligands, Magnesium, Manganese, Models, Chemical, Phosphotransferases, Styrenes, Molecular Structure, HIV-1, HIV Long Terminal Repeat, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Streptavidin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.